Novo Nordisk A/S (WSE:NVO)
Poland · Delayed Price · Currency is PLN | Market Cap | 750.78B -9.0% |
| Revenue (ttm) | 189.42B +5.6% |
| Net Income | 66.95B +4.8% |
| EPS | 15.06 +5.0% |
| Shares Out | n/a |
| PE Ratio | 11.21 |
| Forward PE | 14.93 |
| Dividend | 6.69 (3.80%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 63 |
| Open | 175.10 |
| Previous Close | 169.84 |
| Day's Range | 171.66 - 175.12 |
| 52-Week Range | 129.26 - 231.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
They are way more than just GLP-1 stocks.
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
Novo Nordisk Escalates Weight-Loss War With Eli Lilly
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?
The Wegovy pill missed analysts' expectations in the second quarter. However, Novo Nordisk is still the leader in the market for oral weight loss drugs.
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race
Novo Nordisk CEO Defends Lawsuit Against Eli Lilly (LLY)
Novo Nordisk ($NVO) CEO Mike Doustdar is defending the European drug maker’s lawsuit against U.S. rival Eli Lilly ($LLY) over what it alleges is false advertising about weight-loss medications.
Novo Nordisk Stock (NVO) Falls as CEO Weighs In on Obesity Drug Rivalry with Eli Lilly
Shares in Danish drugmaker Novo Nordisk ($NVO) fell about 2% to roughly $46 per share early Thursday. The decline came even though CEO Mike Doustar told Reuters in an interview…
Novo CEO says obesity market won’t be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take...
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-1 pill, competition in the weight-loss drug space, and more.
Competition has to be fierce, but competition also has to be fair, says Novo Nordisk CEO Doustdar
Novo Nordisk President and CEO Mike Doustdar joins 'Mad Money' host Jim Cramer to talk quarterly results, launching its GLP-q pill, competition in the weight-loss drug space, and more.
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.
Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America
Novo Nordisk CEO argues weight loss drugs could slash health care costs and boost productivity as GLP-1 adoption remains in its early innings.
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market
PHARMA BETS: CEO turns to AI for next-generation drugs
Novo Nordisk President and CEO Mike Doustdar discusses the company's collaboration with artificial intelligence to accelerate drug discovery and development.
Novo Nordisk Stock: Buy or Sell?
Novo Nordisk (NVO -1.17%) is more than just a weight loss company.
Better Buy: Eli Lilly vs. Novo Nordisk
Eli Lilly has a stronger GLP-1 portfolio and pipeline than Novo Nordisk. Eli Lilly also has a better lineup outside the diabetes and weight-loss areas.
Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.
Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.
Novo Nordisk A/S Q2 Earnings Call Highlights
Novo Nordisk A/S NYSE: NVO reported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower real...
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
Eli Lilly should request approval for retatrutide early next year. This medicine could help the company expand the weight loss market.
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound
Berobenatide is one of the keys to Pfizer's future.
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
Novo Nordisk Stock Rises After GLP-1 Antitrust Win
Novo Nordisk price target lowered to DKK 310 from DKK 330 at Citi
Citi lowered the firm’s price target on Novo Nordisk (NVO) to DKK 310 from DKK 330 and keeps a Neutral rating on the shares. The firm views the company’s Q2…
Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market
Eli Lilly and Novo Nordisk have persuaded a U.S. federal judge to dismiss a lawsuit by a compound drug maker that accused the pharmaceutical giants of illegally blocking access to customized versions ...
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk
The holding company beat out incumbent WPP for the U.S. account valued at $520 million.